Renaissance Technologies (RenTech)'s SNDX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 498,200 shares of Syndax Pharmaceuticals, Inc. (SNDX) worth $11.64 M, representing 0.02% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in SNDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 680,965 shares. Largest reduction occurred in Q2 2020, reducing 392,900 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Syndax Pharmaceuticals (SNDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Syndax Pharmaceuticals (SNDX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -46,600 | Reduce 8.55% | 498,200 | $23.36 |
| Q4 2025 | -315,700 | Reduce 36.69% | 544,800 | $21.01 |
| Q3 2025 | +22,800 | Add 2.72% | 860,500 | $15.39 |
| Q2 2025 | +156,273 | Add 22.93% | 837,700 | $9.37 |
| Q1 2025 | +462 | Add 0.07% | 681,427 | $12.29 |
| Q4 2024 | +680,965 | New Buy | 680,965 | $13.22 |
| Q3 2024 | -214,300 | Sold Out | 0 | $0.00 |
| Q2 2024 | +135,200 | Add 170.92% | 214,300 | $20.53 |
| Q1 2024 | +79,100 | New Buy | 79,100 | $23.81 |
| Q4 2023 | -218,300 | Sold Out | 0 | $0.00 |
| Q3 2023 | +218,300 | New Buy | 218,300 | $14.52 |
| Q1 2023 | -81,200 | Sold Out | 0 | $0.00 |
| Q4 2022 | +81,200 | New Buy | 81,200 | $0.03 |
| Q2 2022 | -182,100 | Sold Out | 0 | $0.00 |
| Q1 2022 | +182,100 | New Buy | 182,100 | $17.38 |
| Q3 2020 | -94,700 | Sold Out | 0 | $0.00 |
| Q2 2020 | -392,900 | Reduce 80.58% | 94,700 | $14.82 |
| Q1 2020 | -7,900 | Reduce 1.59% | 487,600 | $10.97 |
| Q4 2019 | -1,500 | Reduce 0.30% | 495,500 | $8.78 |
| Q3 2019 | +65,100 | Add 15.07% | 497,000 | $7.47 |
| Q2 2019 | +117,300 | Add 37.29% | 431,900 | $9.31 |
| Q1 2019 | +85,500 | Add 37.32% | 314,600 | $5.25 |
| Q4 2018 | -50,200 | Reduce 17.97% | 229,100 | $4.45 |
| Q3 2018 | +237,000 | Add 560.28% | 279,300 | $8.08 |
| Q2 2018 | -10,200 | Reduce 19.43% | 42,300 | $7.02 |
| Q1 2018 | +26,800 | Add 104.28% | 52,500 | $14.23 |
| Q4 2017 | +25,700 | New Buy | 25,700 | $8.75 |
Renaissance Technologies (RenTech)'s Syndax Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Syndax Pharmaceuticals, Inc. (SNDX) in Q4 2017, acquiring 25,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Syndax Pharmaceuticals, Inc. (SNDX) for 27 quarters since Q4 2017.
Renaissance Technologies (RenTech)'s largest addition to Syndax Pharmaceuticals, Inc. (SNDX) was in Q4 2024, adding 680,965 shares worth $9 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 498,200 shares of Syndax Pharmaceuticals, Inc. (SNDX), valued at approximately $11.64 M.
As of the Q1 2026 filing, Syndax Pharmaceuticals, Inc. (SNDX) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Syndax Pharmaceuticals, Inc. (SNDX) was 860,500 shares, as reported at the end of Q3 2025.